RAPT RSI Chart
Last 7 days
-1.6%
Last 30 days
-67.9%
Last 90 days
-64.7%
Trailing 12 Months
-65.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 3.2M | 3.2M | 2.3M | 1.5M |
2021 | 5.3M | 4.9M | 4.4M | 3.8M |
2020 | 0 | 0 | 0 | 5.0M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 05, 2024 | brockstedt dirk g. | sold | -20,456 | 22.78 | -898 | chief scientific officer |
Dec 29, 2023 | brockstedt dirk g. | acquired | 49,440 | 6.18 | 8,000 | chief scientific officer |
Dec 21, 2023 | ho william | sold | -54,200 | 21.68 | -2,500 | chief medical officer |
Nov 28, 2023 | ho william | sold | -20,580 | 13.72 | -1,500 | chief medical officer |
Oct 03, 2023 | ho william | sold | -39,425 | 15.77 | -2,500 | chief medical officer |
Aug 18, 2023 | ho william | sold | -47,300 | 18.92 | -2,500 | chief medical officer |
Jul 28, 2023 | ho william | acquired | 5,520 | 12.00 | 460 | chief medical officer |
Jun 23, 2023 | ho william | acquired | 11,040 | 12.00 | 920 | chief medical officer |
Apr 19, 2023 | ho william | sold | -94,400 | 18.88 | -5,000 | chief medical officer |
Apr 13, 2023 | ho william | acquired | 5,520 | 12.00 | 460 | chief medical officer |
Which funds bought or sold RAPT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 18, 2024 | KINGDON CAPITAL MANAGEMENT, L.L.C. | added | 139 | 34,608,800 | 48,001,700 | 3.01% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.63 | 17,469,800 | 51,097,100 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 120 | 6,797,200 | 9,755,070 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.41 | 119,828 | 364,823 | -% |
Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | added | 11.42 | 21,256,400 | 53,177,800 | 1.19% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -33.47 | -2,000 | 508,000 | 0.04% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -3.57 | 25,995,000 | 84,828,000 | 0.01% |
Feb 15, 2024 | BARCLAYS PLC | added | 46.27 | 1,057,000 | 1,949,000 | -% |
Feb 15, 2024 | Farther Finance Advisors, LLC | new | - | 50.00 | 50.00 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | added | 79.4 | 1,190,330 | 1,897,840 | -% |
Unveiling RAPT Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to RAPT Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
RAPT Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | - | - | - | - | 886,000 | 641,000 | 756,000 | 966,000 | 869,000 | 1,222,000 | 1,302,000 | 1,528,000 | 1,277,000 | 935,000 |
Operating Expenses | 36.0% | 33,217,000 | 24,431,000 | 21,678,000 | 19,795,000 | 21,418,000 | 18,790,000 | 19,499,000 | 16,950,000 | 17,783,000 | 14,387,000 | 16,109,000 | 13,788,000 | 13,972,000 |
S&GA Expenses | 29.7% | 6,453,000 | 4,977,000 | 5,079,000 | 5,436,000 | 4,748,000 | 4,491,000 | 3,774,000 | 3,760,000 | 4,012,000 | 3,483,000 | 3,197,000 | 2,802,000 | 3,289,000 |
R&D Expenses | 37.6% | 26,764,000 | 19,454,000 | 16,599,000 | 14,359,000 | 16,670,000 | 14,299,000 | 15,725,000 | 13,190,000 | 13,771,000 | 10,904,000 | 12,912,000 | 10,986,000 | 10,683,000 |
EBITDA Margin | 0.3% | -44.53 | -44.68 | -29.87 | -21.02 | -21.13 | -17.90 | -14.43 | -11.89 | -10.19 | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | 199,000 | 287,000 | 267,000 | 237,000 |
Earnings Before Taxes | - | - | - | - | - | - | -17,929,000 | -18,651,000 | -16,110,000 | -16,514,000 | -12,536,000 | -14,344,000 | -12,120,000 | -12,902,000 |
EBT Margin | 0% | -45.32 | -45.32 | -30.31 | -21.30 | -21.41 | -18.15 | -14.64 | -12.09 | -10.42 | - | - | - | - |
Net Income | -34.5% | -30,876,000 | -22,951,000 | -21,235,000 | -19,184,000 | -20,468,000 | -17,929,000 | -18,651,000 | -16,110,000 | -16,514,000 | -12,735,000 | -14,631,000 | -12,387,000 | -13,139,000 |
Net Income Margin | -39.3% | -76.49 | -54.90 | -34.52 | -23.46 | -22.64 | -18.15 | -14.68 | -12.19 | -10.56 | - | - | - | - |
Free Cashflow | -21.5% | -27,821,000 | -22,898,000 | -17,230,000 | -15,761,000 | -15,727,000 | -21,075,000 | -12,589,000 | -13,980,000 | -14,137,000 | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -13.2% | 173 | 200 | 221 | 248 | 266 | 209 | 222 | 188 | 199 | 217 | 231 | 106 | 119 | 129 | 140 | 151 | 85.00 | 58.00 | 62.00 | 66.00 | 70.00 |
Current Assets | -13.5% | 162 | 187 | 207 | 235 | 253 | 198 | 210 | 176 | 193 | 214 | 228 | 103 | 116 | 126 | 136 | 147 | 81.00 | 51.00 | - | - | 65.00 |
Cash Equivalents | -12.3% | 47.00 | 54.00 | 50.00 | 46.00 | 39.00 | 28.00 | 57.00 | 32.00 | 24.00 | 60.00 | 86.00 | 25.00 | 25.00 | 20.00 | 29.00 | 92.00 | 77.00 | 48.00 | - | - | 64.00 |
Net PPE | -9.5% | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | - | - | 4.00 |
Liabilities | -2.3% | 26.00 | 27.00 | 21.00 | 28.00 | 21.00 | 20.00 | 20.00 | 20.00 | 12.00 | 16.00 | 14.00 | 14.00 | 15.00 | - | - | - | 11.00 | - | - | - | - |
Current Liabilities | -0.1% | 22.00 | 22.00 | 15.00 | 22.00 | 14.00 | 14.00 | 13.00 | 12.00 | 10.00 | 13.00 | 10.00 | 11.00 | 12.00 | 16.00 | 13.00 | 13.00 | 9.00 | 5.00 | - | - | 5.00 |
Shareholder's Equity | -14.9% | 147 | 173 | 200 | 220 | 245 | 189 | 202 | 168 | 186 | 202 | 218 | 92.00 | 104 | 110 | 123 | 132 | 73.00 | - | - | - | - |
Retained Earnings | -6.8% | -484 | -453 | -422 | -397 | -367 | -344 | -323 | -304 | -284 | -266 | -247 | -231 | -214 | -202 | -187 | -175 | -161 | -148 | - | - | -118 |
Additional Paid-In Capital | 0.8% | 632 | 627 | 622 | 617 | 613 | 535 | 527 | 473 | 471 | 468 | 465 | 323 | 319 | 312 | 310 | 307 | 235 | 24.00 | - | - | 22.00 |
Shares Outstanding | -100.0% | - | 38.00 | 38.00 | 38.00 | 34.00 | 34.00 | 30.00 | 30.00 | 30.00 | 27.00 | 25.00 | 25.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 319 | - | - | - | 622 | - | - | - | 437 | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -26.8% | -27,754 | -21,884 | -28,808 | -18,602 | -22,849 | -17,149 | -15,195 | -15,578 | -20,681 | -12,519 | -13,916 | -13,910 | -15,366 | -9,953 | -6,427 | -8,745 | -5,688 | -12,139 | -9,013 | -8,634 | - |
Share Based Compensation | 2.3% | 4,429 | 4,329 | 4,239 | 4,094 | 3,025 | 2,865 | 2,672 | 2,702 | 2,086 | 2,291 | 2,888 | 2,687 | 2,558 | 2,005 | 2,035 | 2,088 | 896 | 431 | 347 | 377 | - |
Cashflow From Investing | -19.8% | 20,639 | 25,749 | 32,437 | 25,308 | -41,270 | -17,599 | -10,458 | 23,837 | -15,892 | -14,174 | -63,692 | 12,411 | 15,495 | 1,060 | -57,009 | -46,981 | 20.00 | -76.00 | -368 | -419 | - |
Cashflow From Financing | 332.1% | 458 | 106 | 767 | 116 | 75,359 | 5,251 | 50,438 | 132 | 601 | 472 | 139,108 | 1,301 | 4,560 | 165 | 864 | 69,872 | 34,741 | 663 | 7,485 | 7,013 | - |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.00 | 109 | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue | $ 0 | $ 1,527 |
Operating expenses: | ||
Research and development | 101,002 | 67,082 |
General and administrative | 26,060 | 20,240 |
Total operating expenses | 127,062 | 87,322 |
Loss from operations | (127,062) | (85,795) |
Other income, net | 10,264 | 1,957 |
Net loss | (116,798) | (83,838) |
Other comprehensive income (loss): | ||
Foreign currency translation gain (loss) | (655) | 627 |
Unrealized gain (loss) on marketable securities | 784 | (447) |
Total comprehensive loss | $ (116,669) | $ (83,658) |
Net loss per share, basic | $ (3.05) | $ (2.58) |
Net loss per share, diluted | $ (3.05) | $ (2.58) |
Weighted average number of shares used in computing net loss per share, basic | 38,338,161 | 32,540,406 |
Weighted average number of shares used in computing net loss per share, diluted | 38,338,161 | 32,540,406 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 47,478 | $ 38,946 |
Marketable securities | 111,384 | 210,122 |
Prepaid expenses and other current assets | 2,920 | 3,626 |
Total current assets | 161,782 | 252,694 |
Property and equipment, net | 2,448 | 2,539 |
Operating lease right-of-use assets | 5,228 | 6,940 |
Other assets | 3,871 | 4,036 |
Total assets | 173,329 | 266,209 |
Current liabilities: | ||
Accounts payable | 5,176 | 3,365 |
Accrued expenses | 14,103 | 8,656 |
Operating lease liabilities, current | 2,448 | 2,171 |
Other current liabilities | 109 | 32 |
Total current liabilities | 21,836 | 14,224 |
Operating lease liabilities, non-current | 4,458 | 6,819 |
Total liabilities | 26,294 | 21,043 |
Commitments (see note 6) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022 | ||
Common stock, $0.0001 par value; 500,000,000 shares authorized; 34,398,312 and 34,254,314 shares issued and outstanding at December 31, 2023 and 2022, respectively | 3 | 3 |
Additional paid-in capital | 631,611 | 613,073 |
Accumulated other comprehensive gain (loss) | 103 | (26) |
Accumulated deficit | (484,682) | (367,884) |
Total stockholders' equity | 147,035 | 245,166 |
Total liabilities and stockholders' equity | $ 173,329 | $ 266,209 |